Interaction Checker

Four cancer drugs have been added to the interaction checker

Thursday 15 March 2018

Alemtuzumab, dabrafenib, obinutuzumab and trametinib have been added to the interaction checker as cancer drugs and interactions can be found for all the comedications.

  • Alemtuzumab (Campath®, MabCampath®) is a monoclonal antibody and is indicated for the treatment of chronic lymphocytic B-cell leukemia.
  • Dabrafenib (Tafinlar®, Rafinlar®) is a BRAF inhibitor and is indicated for the treatment of melanoma.
  • Obinutuzumab (Gazvaro®, Gazyva®) is a monoclonal antibody and is indicated for the treatment of chronic lymphocytic B-cell leukemia.
  • Trametinib (Mekinist®) is a MEK inhibitor and is indicated for the treatment of melanoma.
ENDORSED BY
Bopa